Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$1.89 - $3.27 $317,380 - $549,118
-167,926 Reduced 42.85%
223,970 $450,000
Q4 2023

Feb 09, 2024

SELL
$2.59 - $3.64 $165,192 - $232,162
-63,781 Reduced 14.0%
391,896 $1.18 Million
Q3 2023

Nov 14, 2023

SELL
$3.35 - $4.33 $98,392 - $127,176
-29,371 Reduced 6.06%
455,677 $1.53 Million
Q2 2023

Aug 02, 2023

SELL
$3.63 - $6.38 $35,000 - $61,515
-9,642 Reduced 1.95%
485,048 $2.11 Million
Q1 2023

May 10, 2023

BUY
$3.01 - $3.85 $164,403 - $210,283
54,619 Added 12.41%
494,690 $1.86 Million
Q4 2022

Feb 09, 2023

BUY
$2.04 - $3.53 $169,570 - $293,424
83,123 Added 23.29%
440,071 $1.55 Million
Q3 2022

Nov 15, 2022

BUY
$1.82 - $2.79 $649,645 - $995,884
356,948 New
356,948 $717,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $20.2M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Mai Capital Management Portfolio

Follow Mai Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mai Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Mai Capital Management with notifications on news.